Kay G. Balster

Principal / Authorized signatory

Kay Balster is one of High-Tech Gründerfonds’s longest-serving employees. Since 2009 he has been focusing on financing start-ups from the biotechnology and medical technology sectors. He can draw on 20 years of experience in advising technology start-ups, while his background in economics, training as a banker and especially the day-to-day interaction he has with the founders in his HTGF portfolio help him in his role.

When he is not working, family time and sport are his top priorities.

Portfolio

Exit

Posts & mentions

Press

23. January 2025

Successful exit for HTGF: Health App provider Sonormed becomes part of the InfectoPharm Group

Bonn, 23 January 2025 – InfectoPharm Arzneimittel und Consilium GmbH, a family-owned company specialising in the discovery and further development of pharmaceuticals, is acquiring HTGF portfolio company Sonormed GmbH. Sonormed produces digital health applications (DiGAs) and is a digital health pioneer as the developer of the first app on prescription. High-Tech Gründerfonds (HTGF) was the first institutional investor to invest in Sonormed in 2014 and has closely supported the success

Press

1. August 2023

Bind-X secures €10 million in financing as part of its Series B financing round

Specialist in biological binding of materials expands internationally and prepares further market entries in agriculture, mining, and infrastructure. Martinsried, 1st of August 2023 – Bind-X, a fast-growing industrial biotechnology company, has successfully closed a €10 million financing round. The funding was provided by renowned investors from Germany and abroad (HG Ventures, K&K 1, Greeneering Invest, Saxovent) and will help drive the decarbonization and biologization of es